Interleukin-6 (IL-6) Level as an Indikator of Progresivity Rheumatoid Arthritis (RA) Disease

Authors

  • Putu Oky Ari Tania Bagian Biomedik Penelitian Biomolekuler Fakultas Kedokteran Universitas Wijaya Kusuma Surabaya
  • Dorta Simamora Bagian Biomedik Penelitian Biomolekuler Fakultas Kedokteran Universitas Wijaya Kusuma Surabaya
  • Wahyuni Dyah Parmasari Bagian Gigi dan Mulut Fakultas Kedokteran Universitas Wijaya Kusuma Surabaya
  • Febtarini Rahmawati Bagian Patologi Klinik Fakultas Kedokteran Universitas Wijaya Kusuma Surabaya

DOI:

https://doi.org/10.30742/jikw.v3i1.44

Keywords:

Rheumatoid Arthritis, Disease Progressivity, Interleukin 6 (IL-6)

Abstract

Rheumatoid Arthritis (RA) is autoimmune disease that attacks joints and synovial tissues. Rheumatoid Arthritis is characterized by inflammation that involves production of cytokines such as Interleukin 6 (IL-6). Increasing of interleukin 6 has correlation with activity and progressivity of the disease. This research was designed to know whether IL- 6 could be used as indicator progressivity of RA. The method that used for measuring IL-6 level is ELISA (Enzyme Linked Immunosorbent Assay), using the principle antigen-antibody binding. In early stage there were 9 persons (S01, S02, S03, S04, S07, S08, S09, S10 and S14) with of IL-6 level (mean : 3.640 pg/mL), intermediate stage there were 3 persons (S06, S13 and S15) with IL-6 level (mean : 12.453 pg/mL), late stage : 3 persons (S05, S11 and S12) with IL-6 level (mean : 59.349 pg/mL).

References

Hashizume, M. and M. Mihara, The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis, Arthritis, 2011.

Patel, AM. And LW. Moreland, Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy, Drug Design, Development and Therapy. 2010; 4 : 263–278.

Dewing, KA.,Stephen M. Setter, and Barbara A. Slusher, Osteoarthritis and Rheumatoid Arthritis 2012: Pathophysiology, Diagnosis, and Treatment, Nurse Practitioner Healthcare Foundation, 2012.

McInnes, IB., and G. Schett, The Pathogenesis of Rheumatoid Arthritis, The New England Journal of Medicine, 2011, 365;23.

Grover, HS, N. Gaba, A. Gupta, CN. Marya, Rheumatoid arthritis: a review and dental care considerations, Nepal Med Coll J, 2011; 13(2): 74-76.

Holt, K., A Review of Pathophysiology and Medicinal Treatment Options of Rheumatoid Arthritis, 2011.

Wellby, ML., Kennedy JA., True BS., Barreau P., Serum interleukin-6 and thyroid hormones in rheumatoid arthritis. Metabolism. 2001; 50(4):463-7.

Przybysz, M., K. Borysewicz , J. Szechinski and I. Katnik-Prastowska, Synovial fibronectin fragmentation and domain expressions in relation to rheumatoid arthritis progression, Rheumatology. 2007; 46:1071–1075.

Robak, A. Gladalska, H. Stepie´n and E. Robak. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis, Mediators of Inflammation, 1998; 7: 347–353.

Naka, Tetsuji, N. Nishimoto and T.Kishimoto, The paradigm of IL-6: from basic science to medicine, Arthritis Res, 2002, 4 (suppl 3): S233-S242.

Chung, Soo-Jin, Yong-Jin Kwon, Min-Chan Park, Yong-Beom Park, and Soo-Kon Lee,. The Correlation between Increased Serum Concentrations of Interleukin-6 Family Cytokines and Disease Activity in Rheumatoid Arthritis Patient, Yonsei Med J . 2011; 52(1):113-120.

Alvarez, JLP., Interleukin 6 in the Physiopathology of Rheumatoid Arthritis, Reumatol Clin. 2009; 5(1):34-39.

Ardvidson, NG., Disease Activity in Rheumatoid Arthritis, Doctoral thesis at Uppsala University 2003 from the Department of Medical Sciences. 2003.

Downloads

Published

2017-06-12

Issue

Vol. 3 No. 1 (2014): Edisi Maret 2014

Section

Original Research Article

License

The journal operates an Open Access policy under a Creative Commons Attribution-NonCommercial 4.0 International License. Author continues to retain the copyright if the article is published in this journal. The publisher will only need publishing rights. (CC-BY-NC 4.0)